IL10 and neoplasm: In this case, lenalidomide boosted the persistence and cytotoxicity of CAR-T cells, strengthened the immunological synapse formation between CAR-T cell and myeloma cells, increased the proliferation and expansion of CTLs, induced the secretion of IFN-γ and TNF-α cytokines, and inhibited the production of IL-5 and IL-10 immunosuppressive cytokines, which consequently led to successful tumor cell killing and improved survival in treated mice [116].